| Title |
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates
|
|---|---|
| Published in |
Journal of Clinical Oncology, March 2022
|
| DOI | 10.1200/jco.21.01944 |
| Pubmed ID | |
| Authors |
Chung-Han Lee, Martin H. Voss, Maria Isabel Carlo, Ying-Bei Chen, Mark Zucker, Andrea Knezevic, Robert A. Lefkowitz, Natalie Shapnik, Chloe Dadoun, Ed Reznik, Neil J. Shah, Colette Ngozi Owens, Deaglan Joseph McHugh, David Henry Aggen, Andrew Leonard Laccetti, Ritesh Kotecha, Darren R. Feldman, Robert J. Motzer |
X Demographics
The data shown below were collected from the profiles of 106 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 33 | 31% |
| Spain | 9 | 8% |
| Mexico | 5 | 5% |
| Brazil | 4 | 4% |
| Turkey | 3 | 3% |
| Colombia | 3 | 3% |
| France | 3 | 3% |
| United Kingdom | 3 | 3% |
| India | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 33 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 50 | 47% |
| Practitioners (doctors, other healthcare professionals) | 37 | 35% |
| Scientists | 15 | 14% |
| Science communicators (journalists, bloggers, editors) | 4 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 13% |
| Student > Bachelor | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Professor | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 19 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Nursing and Health Professions | 2 | 5% |
| Agricultural and Biological Sciences | 2 | 5% |
| Unspecified | 1 | 3% |
| Other | 4 | 10% |
| Unknown | 19 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 93. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2023.
All research outputs
#454,006
of 25,392,582 outputs
Outputs from Journal of Clinical Oncology
#910
of 22,059 outputs
Outputs of similar age
#12,730
of 462,336 outputs
Outputs of similar age from Journal of Clinical Oncology
#33
of 380 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,059 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 462,336 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 380 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.